NIVF (NIVF) Stock Price & Analysis
NIVF (NIVF) fell 9.79% to USD 0.49 as of June 10, 2026 at 01:07 UTC, according to Nexqual real-time market data.
NIVF last closed at USD 0.55; the session ranged USD 0.47–0.53 on volume of 959,163 shares. Market capitalization is $1.37M, with a 52-week range of USD 0.47–618 (NCM). Source: Nexqual, June 10, 2026 at 01:07 UTC.
Key Statistics (as of June 10, 2026 at 01:07 UTC)
| Price | USD 0.49 |
|---|---|
| Change | ▼ 9.79% (down) |
| Previous Close | USD 0.55 |
| Open | USD 0.5 |
| Day Range | USD 0.47 – 0.53 |
| 52-Week Range | USD 0.47 – 618 |
| Volume | 959,163 shares |
| Market Cap | $1.37M |
| Exchange | NCM |
Technical Analysis (NIVF)
Nexqual's technical model rates NIVF "SELL" based on 3 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.32 (oversold) |
| vs SMA50 | Below (USD 1.5) |
| MACD | -0.25 (negative) |
Analyst Ratings (NIVF)
Wall Street analysts rate NIVF "Strong Buy" based on 1 analysts, with a mean price target of USD 14.12 (range USD 14.12–14.12), per Nexqual as of June 10, 2026 at 01:07 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 14.12 |
| High Target | USD 14.12 |
| Low Target | USD 14.12 |
| Buy / Hold / Sell | 0 / 0 / 0 |
Earnings (NIVF)
Source: Nexqual, June 10, 2026 at 01:07 UTC.
Financials & Fundamentals (NIVF)
| Total Revenue | $4.73M |
|---|---|
| Revenue Growth (YoY) | +11.90% |
| Gross Margin | +20.22% |
| Operating Margin | -349.13% |
| Profit Margin | +209.03% |
| ROE | +79.40% |
| Debt / Equity | 18.74 |
| Current Ratio | 3.12 |
| Total Cash | $958,556 |
| Total Debt | $4.87M |
| Free Cash Flow | $-10.46M |
Source: Nexqual, June 10, 2026 at 01:07 UTC.
Financial Health Score (NIVF)
Nexqual rates NIVF's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:07 UTC.
| Growth | Solid — Revenue +12% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $959K cash vs $5M debt |
| Cash Flow | Weak — FCF negative: -$10M, burning cash |
| Efficiency | Strong — ROE 79%, ROA -36.9% |
Ownership (NIVF)
| Insider Ownership | +0.04% |
|---|---|
| Institutional Ownership | +20.53% |
| Shares Outstanding | 2.78M |
| Float | 454,771 |
| Short % of Float | +7.00% |
Source: Nexqual, June 10, 2026 at 01:07 UTC.
Leadership (NIVF)
NIVF is led by Wing Fung Siu (age 69), Co-Founder, Chairman & CEO, per Nexqual as of June 10, 2026 at 01:07 UTC.
| Co-Founder, Chairman & CEO | Wing Fung Siu (age 69) |
|---|---|
| Co-Founder, Chief Marketing Officer & Director | Hei Yue Fong (age 43) |
| Chief Financial Officer | Ho Fai Chung (age 61) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TWG | Top Wealth Group Holding Limite | USD 2.4 | ▼ 12.41% |
| MNDR | Mobile-health Network Solutions | USD 0.7 | ▼ 0.27% |
| LRHC | La Rosa Holdings Corp. | USD 1.05 | ▲ 0% |
| BDRX | Biodexa Pharmaceuticals plc | USD 3.1 | ▼ 7.74% |
| TVGN | Tevogen Bio Holdings Inc. | USD 10.75 | ▲ 2.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:07 UTC. This page is informational and not investment advice.